1
|
Chappe Y, Michel P, Joushomme A, Barbeau S, Pierredon S, Baron L, Garenne A, Poulletier De Gannes F, Hurtier A, Mayer S, Lagroye I, Quignard JF, Ducret T, Compan V, Franchet C, Percherancier Y. High-Throughput Screening of Transient Receptor Potential Channel 1 Ligands in the Light of the Bioluminescence Resonance Energy Transfer Technique. Mol Pharmacol 2021; 100:237-257. [PMID: 34127538 DOI: 10.1124/molpharm.121.000271] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2021] [Accepted: 05/17/2021] [Indexed: 11/22/2022] Open
Abstract
Ion channels are attractive drug targets for many therapeutic applications. However, high-throughput screening (HTS) of drug candidates is difficult and remains very expensive. We thus assessed the suitability of the bioluminescence resonance energy transfer (BRET) technique as a new HTS method for ion-channel studies by taking advantage of our recently characterized intra- and intermolecular BRET probes targeting the transient receptor potential vanilloid type 1 (TRPV1) ion channel. These BRET probes monitor conformational changes during TRPV1 gating and subsequent coupling with calmodulin, two molecular events that are intractable using reference techniques such as automated calcium assay (ACA) and automated patch-clamp (APC). We screened the small-sized Prestwick chemical library, encompassing 1200 compounds with high structural diversity, using either intra- and intermolecular BRET probes or ACA. Secondary screening of the detected hits was done using APC. Multiparametric analysis of our results shed light on the capability of calmodulin inhibitors included in the Prestwick library to inhibit TRPV1 activation by capsaicin. BRET was the lead technique for this identification process. Finally, we present data exemplifying the use of intramolecular BRET probes to study other transient receptor potential (TRP) channels and non-TRPs ion channels. Knowing the ease of use of BRET biosensors and the low cost of the BRET technique, these assays may advantageously be included for extending ion-channel drug screening. SIGNIFICANCE STATEMENT: This study screened a chemical library against TRPV1 ion channel using bioluminescence resonance energy transfer (BRET) molecular probes and compared the results with the ones obtained using reference techniques such as automated calcium assay and automated patch-clamp. Multiparametric analysis of our results shed light on the capability of calmodulin antagonists to inhibit chemical activation of TRPV1 and indicates that BRET probes may advantageously be included in ion channel drug screening campaigns.
Collapse
Affiliation(s)
- Yann Chappe
- Bordeaux University, CNRS, IMS Laboratory, UMR5218, F-33400 Talence, France (Y.C., A.J., A.G., F.P.D.G., A.H., I.L., Y.P.); Domain Therapeutics, BIOPARC 1, 850 Boulevard Sébastien Brant, F-67400 Illkirch, France (P.M., L.B., S.M., C.F.); Univ. Bordeaux and INSERM, Centre de Recherche Cardio-Thoracique de Bordeaux, U1045, F-33600 Pessac, France (S.B., J.F.Q., T.D.); and IGF, CNRS, INSERM, Univ. Montpellier, F-34094 Montpellier, France (S.P., V.C.)
| | - Pauline Michel
- Bordeaux University, CNRS, IMS Laboratory, UMR5218, F-33400 Talence, France (Y.C., A.J., A.G., F.P.D.G., A.H., I.L., Y.P.); Domain Therapeutics, BIOPARC 1, 850 Boulevard Sébastien Brant, F-67400 Illkirch, France (P.M., L.B., S.M., C.F.); Univ. Bordeaux and INSERM, Centre de Recherche Cardio-Thoracique de Bordeaux, U1045, F-33600 Pessac, France (S.B., J.F.Q., T.D.); and IGF, CNRS, INSERM, Univ. Montpellier, F-34094 Montpellier, France (S.P., V.C.)
| | - Alexandre Joushomme
- Bordeaux University, CNRS, IMS Laboratory, UMR5218, F-33400 Talence, France (Y.C., A.J., A.G., F.P.D.G., A.H., I.L., Y.P.); Domain Therapeutics, BIOPARC 1, 850 Boulevard Sébastien Brant, F-67400 Illkirch, France (P.M., L.B., S.M., C.F.); Univ. Bordeaux and INSERM, Centre de Recherche Cardio-Thoracique de Bordeaux, U1045, F-33600 Pessac, France (S.B., J.F.Q., T.D.); and IGF, CNRS, INSERM, Univ. Montpellier, F-34094 Montpellier, France (S.P., V.C.)
| | - Solène Barbeau
- Bordeaux University, CNRS, IMS Laboratory, UMR5218, F-33400 Talence, France (Y.C., A.J., A.G., F.P.D.G., A.H., I.L., Y.P.); Domain Therapeutics, BIOPARC 1, 850 Boulevard Sébastien Brant, F-67400 Illkirch, France (P.M., L.B., S.M., C.F.); Univ. Bordeaux and INSERM, Centre de Recherche Cardio-Thoracique de Bordeaux, U1045, F-33600 Pessac, France (S.B., J.F.Q., T.D.); and IGF, CNRS, INSERM, Univ. Montpellier, F-34094 Montpellier, France (S.P., V.C.)
| | - Sandra Pierredon
- Bordeaux University, CNRS, IMS Laboratory, UMR5218, F-33400 Talence, France (Y.C., A.J., A.G., F.P.D.G., A.H., I.L., Y.P.); Domain Therapeutics, BIOPARC 1, 850 Boulevard Sébastien Brant, F-67400 Illkirch, France (P.M., L.B., S.M., C.F.); Univ. Bordeaux and INSERM, Centre de Recherche Cardio-Thoracique de Bordeaux, U1045, F-33600 Pessac, France (S.B., J.F.Q., T.D.); and IGF, CNRS, INSERM, Univ. Montpellier, F-34094 Montpellier, France (S.P., V.C.)
| | - Luc Baron
- Bordeaux University, CNRS, IMS Laboratory, UMR5218, F-33400 Talence, France (Y.C., A.J., A.G., F.P.D.G., A.H., I.L., Y.P.); Domain Therapeutics, BIOPARC 1, 850 Boulevard Sébastien Brant, F-67400 Illkirch, France (P.M., L.B., S.M., C.F.); Univ. Bordeaux and INSERM, Centre de Recherche Cardio-Thoracique de Bordeaux, U1045, F-33600 Pessac, France (S.B., J.F.Q., T.D.); and IGF, CNRS, INSERM, Univ. Montpellier, F-34094 Montpellier, France (S.P., V.C.)
| | - André Garenne
- Bordeaux University, CNRS, IMS Laboratory, UMR5218, F-33400 Talence, France (Y.C., A.J., A.G., F.P.D.G., A.H., I.L., Y.P.); Domain Therapeutics, BIOPARC 1, 850 Boulevard Sébastien Brant, F-67400 Illkirch, France (P.M., L.B., S.M., C.F.); Univ. Bordeaux and INSERM, Centre de Recherche Cardio-Thoracique de Bordeaux, U1045, F-33600 Pessac, France (S.B., J.F.Q., T.D.); and IGF, CNRS, INSERM, Univ. Montpellier, F-34094 Montpellier, France (S.P., V.C.)
| | - Florence Poulletier De Gannes
- Bordeaux University, CNRS, IMS Laboratory, UMR5218, F-33400 Talence, France (Y.C., A.J., A.G., F.P.D.G., A.H., I.L., Y.P.); Domain Therapeutics, BIOPARC 1, 850 Boulevard Sébastien Brant, F-67400 Illkirch, France (P.M., L.B., S.M., C.F.); Univ. Bordeaux and INSERM, Centre de Recherche Cardio-Thoracique de Bordeaux, U1045, F-33600 Pessac, France (S.B., J.F.Q., T.D.); and IGF, CNRS, INSERM, Univ. Montpellier, F-34094 Montpellier, France (S.P., V.C.)
| | - Annabelle Hurtier
- Bordeaux University, CNRS, IMS Laboratory, UMR5218, F-33400 Talence, France (Y.C., A.J., A.G., F.P.D.G., A.H., I.L., Y.P.); Domain Therapeutics, BIOPARC 1, 850 Boulevard Sébastien Brant, F-67400 Illkirch, France (P.M., L.B., S.M., C.F.); Univ. Bordeaux and INSERM, Centre de Recherche Cardio-Thoracique de Bordeaux, U1045, F-33600 Pessac, France (S.B., J.F.Q., T.D.); and IGF, CNRS, INSERM, Univ. Montpellier, F-34094 Montpellier, France (S.P., V.C.)
| | - Stanislas Mayer
- Bordeaux University, CNRS, IMS Laboratory, UMR5218, F-33400 Talence, France (Y.C., A.J., A.G., F.P.D.G., A.H., I.L., Y.P.); Domain Therapeutics, BIOPARC 1, 850 Boulevard Sébastien Brant, F-67400 Illkirch, France (P.M., L.B., S.M., C.F.); Univ. Bordeaux and INSERM, Centre de Recherche Cardio-Thoracique de Bordeaux, U1045, F-33600 Pessac, France (S.B., J.F.Q., T.D.); and IGF, CNRS, INSERM, Univ. Montpellier, F-34094 Montpellier, France (S.P., V.C.)
| | - Isabelle Lagroye
- Bordeaux University, CNRS, IMS Laboratory, UMR5218, F-33400 Talence, France (Y.C., A.J., A.G., F.P.D.G., A.H., I.L., Y.P.); Domain Therapeutics, BIOPARC 1, 850 Boulevard Sébastien Brant, F-67400 Illkirch, France (P.M., L.B., S.M., C.F.); Univ. Bordeaux and INSERM, Centre de Recherche Cardio-Thoracique de Bordeaux, U1045, F-33600 Pessac, France (S.B., J.F.Q., T.D.); and IGF, CNRS, INSERM, Univ. Montpellier, F-34094 Montpellier, France (S.P., V.C.)
| | - Jean-François Quignard
- Bordeaux University, CNRS, IMS Laboratory, UMR5218, F-33400 Talence, France (Y.C., A.J., A.G., F.P.D.G., A.H., I.L., Y.P.); Domain Therapeutics, BIOPARC 1, 850 Boulevard Sébastien Brant, F-67400 Illkirch, France (P.M., L.B., S.M., C.F.); Univ. Bordeaux and INSERM, Centre de Recherche Cardio-Thoracique de Bordeaux, U1045, F-33600 Pessac, France (S.B., J.F.Q., T.D.); and IGF, CNRS, INSERM, Univ. Montpellier, F-34094 Montpellier, France (S.P., V.C.)
| | - Thomas Ducret
- Bordeaux University, CNRS, IMS Laboratory, UMR5218, F-33400 Talence, France (Y.C., A.J., A.G., F.P.D.G., A.H., I.L., Y.P.); Domain Therapeutics, BIOPARC 1, 850 Boulevard Sébastien Brant, F-67400 Illkirch, France (P.M., L.B., S.M., C.F.); Univ. Bordeaux and INSERM, Centre de Recherche Cardio-Thoracique de Bordeaux, U1045, F-33600 Pessac, France (S.B., J.F.Q., T.D.); and IGF, CNRS, INSERM, Univ. Montpellier, F-34094 Montpellier, France (S.P., V.C.)
| | - Vincent Compan
- Bordeaux University, CNRS, IMS Laboratory, UMR5218, F-33400 Talence, France (Y.C., A.J., A.G., F.P.D.G., A.H., I.L., Y.P.); Domain Therapeutics, BIOPARC 1, 850 Boulevard Sébastien Brant, F-67400 Illkirch, France (P.M., L.B., S.M., C.F.); Univ. Bordeaux and INSERM, Centre de Recherche Cardio-Thoracique de Bordeaux, U1045, F-33600 Pessac, France (S.B., J.F.Q., T.D.); and IGF, CNRS, INSERM, Univ. Montpellier, F-34094 Montpellier, France (S.P., V.C.)
| | - Christelle Franchet
- Bordeaux University, CNRS, IMS Laboratory, UMR5218, F-33400 Talence, France (Y.C., A.J., A.G., F.P.D.G., A.H., I.L., Y.P.); Domain Therapeutics, BIOPARC 1, 850 Boulevard Sébastien Brant, F-67400 Illkirch, France (P.M., L.B., S.M., C.F.); Univ. Bordeaux and INSERM, Centre de Recherche Cardio-Thoracique de Bordeaux, U1045, F-33600 Pessac, France (S.B., J.F.Q., T.D.); and IGF, CNRS, INSERM, Univ. Montpellier, F-34094 Montpellier, France (S.P., V.C.)
| | - Yann Percherancier
- Bordeaux University, CNRS, IMS Laboratory, UMR5218, F-33400 Talence, France (Y.C., A.J., A.G., F.P.D.G., A.H., I.L., Y.P.); Domain Therapeutics, BIOPARC 1, 850 Boulevard Sébastien Brant, F-67400 Illkirch, France (P.M., L.B., S.M., C.F.); Univ. Bordeaux and INSERM, Centre de Recherche Cardio-Thoracique de Bordeaux, U1045, F-33600 Pessac, France (S.B., J.F.Q., T.D.); and IGF, CNRS, INSERM, Univ. Montpellier, F-34094 Montpellier, France (S.P., V.C.)
| |
Collapse
|